Previous Close | 56.38 |
Open | 57.38 |
Bid | 55.56 x 1300 |
Ask | 59.85 x 900 |
Day's Range | 56.73 - 60.20 |
52 Week Range | 43.46 - 117.86 |
Volume | |
Avg. Volume | 774,493 |
Market Cap | 3.583B |
Beta (5Y Monthly) | 0.96 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -11.06 |
Earnings Date | Jul 27, 2022 - Aug 01, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 95.57 |
Subscribe to Yahoo Finance Plus to view Fair Value for BPMC
Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Habib Dable to its board of directors. Mr. Dable, who was Chief Executive Officer of Acceleron Pharma from 2016 to 2021, brings nearly 30 years of experience in strategic leadership, commercial growth and organizational scale across global pharmaceutical and emerging biotechnology companies.
Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved to treat rare cancer and other rare diseases, has seen strong uptake since approval. However, stiff competition remains a concern.
The FDA recommended Blueprint Medicines change the ultimate goal of a midstage study, leading BPMC stock to crumble Thursday.